Characterization of murine JAK2V617F-positive myeloproliferative disease

Cancer Research

Volumn 66, Issue 23, 2006, Pages 11156-11165

  Bumm, Thomas G P ^a   Elsea, Collin ^a   Corbin, Amie S ^a,c   Loriaux, Marc ^a,b   Sherbenou, Daniel ^a   Wood, Lisa ^a   Deininger, Jutta ^b   Silver, Richard T ^d   Druker, Brian J ^a,c   Deininger, Michael W N ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JANUS KINASE 2; TUMOR NECROSIS FACTOR ALPHA; ERYTHROPOIETIN; JAK2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; BONE MARROW; CELL SELECTION; ERYTHROBLAST; ERYTHROCYTOSIS; ERYTHROID PRECURSOR CELL; EXTRAMEDULLARY HEMATOPOIESIS; GENE MUTATION; GENETIC ANALYSIS; GRANULOCYTOSIS; HEMATOPOIESIS; MEGAKARYOCYTE; MOUSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN; THROMBOEMBOLISM; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL CLONE; CELL LINE; FIBROSIS; GENETIC TRANSFECTION; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; METABOLISM; METHODOLOGY; MISSENSE MUTATION; PATHOLOGY; POLYCYTHEMIA; POLYCYTHEMIA VERA; TIME;

ANIMALS; BONE MARROW; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL LINE; CLONE CELLS; ERYTHROPOIETIN; FIBROSIS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS, EXTRAMEDULLARY; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MICE; MICE, INBRED BALB C; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA; POLYCYTHEMIA VERA; RECEPTORS, ERYTHROPOIETIN; SPLEEN; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845798378     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2210     Document Type: Article

References (42)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-5.
2. Vardiman JW, Pierre R, Thiele J, Imbert M, Brunning RD, Flandrin G. Chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 15-59.
3. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
4. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIPILI genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
9. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-8.
10. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005;106:1207-9.
11. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:3377-9.
12. Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001;14:27-37.
13. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-95.
14. Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93:397-409.
15. Dai CH, Krantz SB, Dessypris EN, et al. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992;80:891-9.
16. Casadevall N, Vainchenker W, Lacombe C, et al. Erythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures. Blood 1982;59:447-51.
17. James H, Mills K, Gibson I. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation. Leukemia 1996;10:1676.
18. Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polyeythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274-81.
19. Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108:1652-60.
20. Ghaffari S, Kitidis C, Zhao W, et al. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood 2006;107:1888-91.
21. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2003;200-24.
22. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.
23. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006;132:244-5.
24. Bunting KD, Yu WM, Bradley HL, et al. Increased numbers of committed myeloid progenitors but not primitive hematopoietic stem/progenitors in mice lacking STAT6 expression. J Leukoc Biol 2004;76:484-90.
25. Armstrong L, Stojkovic M, Dimmick I, et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004;22:1142-51.
26. Bozzini CE, Barrio Rendo ME, Devoto FC, Epper CE. Studies on medullary and extramedullary erythropoiesis in the adult mouse. Am J Physiol 1970;219:724-8.
27. Huntly BJP, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005;5:311-21.
28. Curtis DJ, Hall MA, Van Stekelenburg LJ, et al. SCL is required for normal function of short-term repopulating hematopoietic stem cells. Blood 2004;103:3342-8.
29. Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 2006;103:6224-9.
30. Suzuki N, Suwabe N, Ohneda O, et al. Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. Blood 2003;102:3575-83.
31. Nakorn TN, Miyamoto T, Weissman IL. Characterization of mouse clonogenic megakaryocyte progenitors. Proc Natl Acad Sci U S A 2003;100:205-10.
32. Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6, and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005;130:709-15.
33. Zeuner A, Pedini F, Signore M, et al. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood 2006;107:3495-502.
34. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005;102:18962-7.
35. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179-87.
36. + cells. Exp Hematol 2002;30:1238-47.
37. Jacobs-Helber SM, Roh KH, Bailey D, et al. Tumor necrosis factor-α expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood 2003;101:524-31.
38. Battegay EJ, Raines EW, Colbert T, Ross R. TNF-α stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol 1995;154:6040-7.
39. Smith BD, La Celle PL. Blood viscosity and thrombosis: clinical considerations. Prog Hemost Thromb 1982;6:179-201.
40. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-6.
41. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92:3780-92.
42. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004;6:587-96.